Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells (Q39968040)

16 September 2017

Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells (English)

1 reference

16 September 2017

1 reference

1 reference

Manon E Wildenberg

1

1 reference

16 September 2017

Cornelia G van Helden-Meeuwsen

2

1 reference

16 September 2017

Joop P van de Merwe

3

1 reference

16 September 2017

Hemmo A Drexhage

4

1 reference

16 September 2017

Marjan A Versnel

5

1 reference

16 September 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

European Journal of Immunology

16 September 2017

1 reference

16 September 2017

38

1 reference

16 September 2017

2024-2033

1 reference

16 September 2017

7

1 reference

Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions

16 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Anti-alpha-fodrin antibodies in Sjögren syndrome and lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Differential immunological aberrations in patients with primary and secondary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Abnormal B cell differentiation in primary Sjögren's syndrome results in a depressed percentage of circulating memory B cells and elevated levels of soluble CD27 that correlate with Serum IgG concentration.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Type I interferons (alpha/beta) in immunity and autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Links between innate and adaptive immunity via type I interferon

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Type I interferons produced by dendritic cells promote their phenotypic and functional activation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Plasmacytoid dendritic cells in immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Reduced blood BDCA-2+ (lymphoid) and CD11c+ (myeloid) dendritic cells in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Decreased blood dendritic cell counts in type 1 diabetic children

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Serum interferon levels in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Type I interferon correlates with serological and clinical manifestations of SLE

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Viral infection switches non-plasmacytoid dendritic cells into high interferon producers.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

BAFF overexpression is associated with autoantibody production in autoimmune diseases

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Sjögren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Induction of clinical autoimmune disease by therapeutic interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Cross-regulation of TNF and IFN-alpha in autoimmune diseases

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Exploration, normalization, and summaries of high density oligonucleotide array probe level data

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Maximum significance clustering of oligonucleotide microarrays.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200738008

7 January 2021

Identifiers

DOI

10.1002/EJI.200738008

1 reference

16 September 2017

1 reference